Transforming Growth Factor Beta 1 (TGFB1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-ß1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation, and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 41 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 10, 1, 14 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Musculoskeletal Disorders, Ophthalmology, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Genetic Disorders, Infectious Disease, Cardiovascular, Central Nervous System, Dermatology, Hematological Disorders and Male Health which include indications Solid Tumor, Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Non-Small Cell Lung Cancer, Colorectal Cancer, Kidney Fibrosis, Liver Fibrosis, Myelofibrosis, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Diabetic Nephropathy, Fibrosis, Liver Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Squamous Cell Carcinoma, Bladder Cancer, Corneal Dystrophy, Coronavirus Disease 2019 (COVID-19), Glioblastoma Multiforme (GBM), Melanoma, Metastatic Liver Cancer, Non-Alcoholic Steatohepatitis (NASH), Osteoarthritis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Sclerosing Cholangitis, Renal Cell Carcinoma, Systemic Sclerosis (Scleroderma), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Unspecified Cancer, Age Related Macular Degeneration, Alport Syndrome, Anemia, Basal Cell Carcinoma (Basal Cell Epithelioma), Benign Prostatic Hyperplasia, Bone Disorders, Cholangitis, Choroidal Neovascularization, Colitis, Colon Cancer, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Glaucoma, Gynecological Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hyperalgesia, Hypertrophic Scars, Inflammation, Interstitial Lung Fibrosis, Keloids, Lung Adenocarcinoma, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Nonmelanomatous Skin Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatitis Pain, Proliferative Vitreoretinopathy (PVR), Pulmonary Hypertension and Transitional Cell Cancer (Urothelial Cell Cancer).

The latest report Transforming Growth Factor Beta 1 (TGFB1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
• The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1) Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope